SML0971
Ki 16425
≥98% (HPLC)
Synonym(s):
3-[[[4-[4-[[[1-(2-Chlorophenyl)ethoxy]carbonyl]amino]-3-methyl-5-isoxazolyl]phenyl]methyl]thio]-propanoic acid, Ki16425
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C23H23ClN2O5S
CAS Number:
Molecular Weight:
474.96
UNSPSC Code:
12352200
NACRES:
NA.77
Quality Level
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 20 mg/mL, clear
storage temp.
−20°C
SMILES string
S(CCC(=O)O)Cc1ccc(cc1)c2[o]nc(c2NC(=O)OC(C)c3c(cccc3)Cl)C
InChI
1S/C23H23ClN2O5S/c1-14-21(25-23(29)30-15(2)18-5-3-4-6-19(18)24)22(31-26-14)17-9-7-16(8-10-17)13-32-12-11-20(27)28/h3-10,15H,11-13H2,1-2H3,(H,25,29)(H,27,28)
InChI key
LLIFMNUXGDHTRO-UHFFFAOYSA-N
Application
Ki 16425 has been used as a chemical inhibitor to study the regulation of LPA (lysophosphatidic acid) on LPAR(LPA receptor) subtypes.
Biochem/physiol Actions
Ki16452 is a potent antagonist of the lysophosphatidic acid receptors LPA1 and LPA3, with greater than 30-fold selectivity for LPA1 over LPA2. The Ki values for LPA1 and LPA3 are 250 nM and 360 nM, respectively.
Ki16452 is a potent antagonist of the lysophosphatidic acid receptors LPA1 and LPA3.
Ki 16425 possesses a short-lived inhibitory activity. It has been studied that Ki 16425 is effective in the inhibition of neuropathic pain‐like behaviors.
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Evidence for lysophosphatidic acid 1 receptor signaling in the early phase of neuropathic pain mechanisms in experiments using Ki?16425, a lysophosphatidic acid 1 receptor antagonist.
Ma L, et al.
Journal of Neurochemistry, 109(2), 603-610 (2009)
Jean-Philippe Pradère et al.
Journal of the American Society of Nephrology : JASN, 18(12), 3110-3118 (2007-11-16)
Tubulointerstitial fibrosis in chronic renal disease is strongly associated with progressive loss of renal function. We studied the potential involvement of lysophosphatidic acid (LPA), a growth factor-like phospholipid, and its receptors LPA(1-4) in the development of tubulointerstitial fibrosis (TIF). Renal
Jennifer Fransson et al.
Molecular neurobiology, 58(2), 470-482 (2020-09-26)
Multiple sclerosis (MS) is a neuroinflammatory disease whose pathogenesis remains unclear. Lysophosphatidic acid (LPA) is an endogenous phospholipid involved in multiple immune cell functions and dysregulated in MS. Its receptor LPA1 is expressed in macrophages and regulates their activation, which
Global Trade Item Number
| SKU | GTIN |
|---|---|
| SML0971-5MG | 04061837107450 |
| SML0971-25MG | 04061833224465 |